Table 4.

Key human pharmacokinetic parameters for selected small-molecule drugs NOT approved for oncology indications

Generic nameBrand nameDoseDose unitRouteInfusionCmax (μmol/L)Cmax (ng/mL)AUC (ng•hr/mL)Tmax (hr)T1/2 (hr)Protein binding
AlfuzosinUroXatral10mgPO0.035141948.01082%–90%
AminoglutethimideCytadren500mgPO25.45,9001.512.521%–25%
CelecoxibCelebrex400mgPO4.601,75213,0498.897%
ChloroquineAralen750mgPO0.7252328,3853.755%
DutasterideAvodart0.5mgPO0.076402–384099%
FinasterideProscar5mgPO0.124463891.8690%
Histrelin acetateSupprelin0.0567mg/daySC0.000831.12,3181270%
HydroxychloroquinePlaquenil200mgPO0.35000117.412,0153.856445%
IbandronateBoniva6mgIV30 min1.023279420.631286%
Medroxyprogesterone acetateProvera20mgPO0.00261.06.952.712.190%
MetforminGlucophage1,500mgPO24.03,10018,4001.55.98Negligible
QuinacrineAcrichine100mgPO0.30012080%–90%
SildenafilViagra100mgPO0.7943771,2951.02.7696%
Sirolimus (rapamycin)Rapamune2mgPO0.016152303.56292%
TacrolimusPrograf5mgPO0.037302431.634.899%
Zalcitabine (dideoxycytidine)Hivid1.5mgPO0.11925720.80<4%
  • Abbreviations: min, minutes; PO, per os; SC, subcutaneous; Tmax: time post-dose of maximum plasma concentration; T1/2: plasma half-life.